OP30 Obefazimod shows first evidence of anti-fibrotic activity in preclinical models of inflammatory bowel disease

医学 炎症性肠病 溃疡性结肠炎 纤维化 体内 炎症 胃肠病学 任天堂 内科学 细胞因子 结肠炎 组织学 成纤维细胞 药代动力学 病理 促炎细胞因子 免疫学 布地奈德 药理学 克罗恩病 体外 临床试验 托法替尼 疾病
作者
S Danese,Francisco A. Costa Magro,Britta Siegmund,Raja Atreya,J Santo,Aude Garcel,Silvia D’Alessio,Martin Pehrsson,Joachim Høg Mortensen,M Sorokina Alexdóttir,A C Bay-Jensen,M A Karsdal,R Mosig,C Rabbat,M de la Rosa,F Cataldi,Bram Verstock
出处
期刊:Journal of Crohn's and Colitis [Oxford University Press]
卷期号:20 (Supplement_1)
标识
DOI:10.1093/ecco-jcc/jjaf231.030
摘要

Abstract Background Obefazimod (Obe) is an oral, first-in-class enhancer of the anti-inflammatory microRNA miR-1241 showing efficacy and safety in ulcerative colitis (UC) patients2-4. A major complication of chronic inflammation in inflammatory bowel disease (IBD) is fibrosis, particularly in Crohn’s disease (CD). To date, no efficacious anti-fibrotic treatment for IBD patients is available. As miR-124 is reduced in fibrotic tissue and can suppress TGF-β, a central driver of fibrogenesis, we assessed whether Obe-mediated miR-124 induction affects collagen deposition and fibrotic markers in preclinical models. Methods Two sets of experiments were performed to assess the anti-fibrotic effects of Obe: (A) In vitro fibrosis was evaluated in the Scar-in-a-Jar (SiaJ) model using human small-intestinal fibroblasts, stimulated with an IBD-fibrotic cytokine cocktail (IBD-FC). Nintedanib, omipalisib and upadacitinib were used as comparators. Readouts included cytotoxicity, PRO-C3, and α-SMA. (B) In vivo effects were assessed in the chronic TNBS-colitis mouse model, where Obe (100 mg/kg) or control (vehicle or thalidomide) were administered orally either from day 5 (anti-inflammatory + fibrosis-preventive effect) or from day 20 (early-onset anti-fibrotic effect). Disease activity, body weight, colon parameters, histology and collagen deposition were analyzed. Statistics: ANOVA with multiple comparisons. Results In vitro, Obe induced a significant 50% reduction in PRO-C3 at day 12, compared with the IBD-FC condition and upadacitinib (live-cell–adjusted, p < 0.0001 vs. IBD-FC; Fig. 1A). Notably, the IBD-FC SiaJ assay showed pathway specificity: nintedanib showed no activity, while omipalisib did (Fig 1B). Additionally, cell-number–adjusted analysis showed significant α-SMA reduction by Obe indicating a strong inhibition of fibroblast activation (p < 0.0001 vs. IBD-FC, Fig 1B). In vivo, the known anti-inflammatory effects of Obe were confirmed in the chronic colitis model under both dosing schedules (Fig. 2A). Moreover, results from this initial experiment showed a reduction in the fibrosis score (Fig. 2B) and collagen deposition was reduced by ∼52% with day 5 dosing and ∼42% with day 20 dosing in the Sirius Red assay, whereas thalidomide as a positive control achieved ∼24%. (Fig. 2C). Conclusion These data support an anti-fibrotic effect of Obe in two well-established models, inhibiting collagen deposition and fibroblast activation. Initial in vivo mouse data, aligned with the in vitro findings, indicate that Obe may act in a unique way on both intestinal inflammation and fibrosis. These promising results provide a strong rationale to further investigate Obe’s anti-fibrotic potential in the ongoing phase 2b Crohn’s disease trial (NCT#06456593). References: 1.Apolit C et al. Clin Transl Gastroenterol. 2023;14(4):e00560 2.Vermeire S, et al. J Crohns Colitis. 2023; 17: 1689-1697 3.Vermeire S, et al. Gastroenterology 2021; 160: 2595-2598 4.Vermeire S, et al. The Lancet Gastroenterology & Hepatology. 2022; 7: 1024-1035 Conflict of interest: Danese, Silvio: Personal Fees: AbbVie, Alimentiv, Allergan, Amgen, Applied Molecular Transport, AstraZeneca, Athos Therapeutics, Biogen, Boehringer Ingelheim, Bristol Myers Squibb, Celgene, Celltrion, Dr Falk Pharma, Eli Lilly, Enthera, Ferring Pharmaceuticals Inc., Gilead, Hospira, Inotrem, Janssen, Johnson & Johnson, Morphic, MSD, Mundipharma, Mylan, Pfizer, Roche, Sandoz, Sublimity Therapeutics, Takeda, Teladoc Health, TiGenix, UCB Inc., Vial, Vifor Lecture fees from Abbvie, Amgen, Ferring Pharmaceuticals Inc., Gilead, Janssen, Mylan, Pfizer, Takeda Magro, Fernando: Fernando Magro served as speaker and received honoraria from Abbvie, Arena, Biogen, Bristol-Myers Squibb, Falk, Ferring, Hospira, Janssen, Laboratórios Vitoria, Pfizer, Lilly, Merck Sharp & Dohme, Sandoz, Takeda, UCB, Vifor. Siegmund, Britta: Grant: Pfizer Other: Consultant: Abbvie, Abivax, Boehringer Ingelheim, Bristol Myers Squibb, Dr. Falk Pharma, Eli Lilly, Endpoint Health, Galapagos, Janssen/Johnson & Johnson, Materia Prima, MSD, Pfizer, Takeda, Wedbush Securities. Speaker: Abbvie, AlfaSigma, Bristol Myers Squibb, CED Service GmbH, Dr. Falk Pharma, Eli Lilly, Ferring, Galapagos, Janssen/Johnson & ampJohnson, MD Education, MSD, Pfizer, Tr1xBio. Atreya, Raja: RA has served as a speaker, or consultant, or received research grants from AbbVie, Abivax, AlfaSigma, Arena Pharmaceuticals, Astra-Zeneca, Biogen, Boehringer Ingelheim, Bristol-Myers Squibb, Celgene, Celltrion Healthcare, Dr Falk Pharma, Galapagos, Gilead, GlaxoSmithKline, InDex Pharmaceuticals, Johnson & Johnson, Lilly, Materia Prima, Merck Sharpe & Dohme, Pfizer, Roche Pharma, Takeda Pharma, Viatris. Santo, Julien: Employee of Abivax Garcel, Aude: Employee of Abivax D’Alessio, Silvia: I have served as a consultant for Ferring Pharmaceuticals, Cytoki Pharma, Dompè, Takeda, Attovia, Surrozen, Enthera Pehrsson, Martin: Employed at Nordic Bioscience A/S Mortensen, Joachim: Fulltime employee and stock owner at Nordic Bioscience Sorokina Alexdóttir, Marta: Fulltime employee at Nordic Bioscience Bay-Jensen, Anne-Christine: Fulltime employee and stock owner at Nordic Bioscience Karsdal, Morten Asser: Fulltime employee and stock owner at Nordic Bioscience Mosig, Rebecca: Employee of Abivax Rabbat, Chris: Employee of Pfizer, Inc. de la Rosa, Maurus: Employee of Abivax Cataldi, Fabio: Abivax Verstockt, Bram: - Research support from AbbVie, Biora Therapeutics, Celltrion, Landos, Pfizer, Sanofi, Sossei Heptares/Nxera and Takeda. - Speaker’s fees from Abbvie, Agomab, Alfasigma, Biogen, Bristol Myers Squibb, Celltrion, Eli Lily, Falk, Ferring, Galapagos, Materia Prima, Johnson and Johnson, Pfizer, Sandoz, Takeda, Tillots Pharma, Truvion and Viatris. - Consultancy fees from Abbvie, Alfasigma, Alimentiv, Anaptys Bio, Applied Strategic, Astrazeneca, Atheneum, BenevolentAI, Biora Therapeutics, Boxer Capital, Bristol Myers Squibb, Domain Therapeutics, Eli Lily, Galapagos, Guidepont, Landos, Merck, Mirador Therapeutics, Mylan, Nxera, Inotrem, Ipsos, Johnson and Johnson, Pfizer, Sandoz, Sanofi, Santa Ana Bio, Sapphire Therapeutics, Sosei Heptares, Takeda, Tillots Pharma and Viatris. - Stock options Vagustim and Thethis Pharma.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
刚刚
温山先生发布了新的文献求助10
刚刚
1秒前
安稳的乐松完成签到,获得积分20
1秒前
默默发布了新的文献求助10
2秒前
3秒前
Anita完成签到,获得积分20
4秒前
4秒前
粗心的从露完成签到,获得积分10
5秒前
乔治发布了新的文献求助10
5秒前
bkagyin的应助被冬至采纳,获得10
6秒前
lilili发布了新的文献求助10
6秒前
6秒前
Hello的应助被华熙采纳,获得40
6秒前
一枝清荷发布了新的文献求助10
7秒前
7秒前
yyds的应助被鱼籽派采纳,获得10
8秒前
高大的柜子完成签到 ,获得积分10
8秒前
syvshc的应助被jessie采纳,获得10
8秒前
moshang完成签到 ,获得积分10
9秒前
9秒前
xfy发布了新的文献求助200
9秒前
10秒前
11秒前
香蕉觅云的应助被Liu采纳,获得10
11秒前
huoyunli发布了新的文献求助10
11秒前
yuan完成签到,获得积分20
12秒前
彦页关注了科研通微信公众号
12秒前
含糊的剑封完成签到,获得积分10
12秒前
Sunny完成签到,获得积分10
12秒前
li完成签到 ,获得积分10
13秒前
13秒前
汉堡包的应助被顺利采纳,获得10
13秒前
兰州2026完成签到 ,获得积分10
14秒前
14秒前
yyy完成签到,获得积分10
15秒前
15秒前
15秒前
在水一方的应助被暴龙战士采纳,获得10
16秒前
16秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 2000
Handbook of Sport Coaching Research 1000
Orthognathic Surgery - 2 Volume Set 500
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
基于结构调控的功能化水诱导发电材料与器件研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8193514
求助须知:如何正确求助?哪些是违规求助? 9579686
关于积分的说明 21866883
捐赠科研通 7793152
什么是DOI,文献DOI怎么找? 3437297
关于科研通互助平台的介绍 2560725
邀请新用户注册赠送积分活动 2484176